Lead Product(s) : CAS 135097-63-1
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tbo-Filgrastim is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 23, 2017
Lead Product(s) : CAS 135097-63-1
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
